Related references
Note: Only part of the references are listed.Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays
Aleksandra Urban et al.
AUTOIMMUNITY (2018)
Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment
Styliani I. Kokoris et al.
HEMATOLOGY (2018)
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody
Mark T. Winkler et al.
PLOS ONE (2017)
New perspectives on complement mediated immunotherapy
Grzegorz Stasilojc et al.
CANCER TREATMENT REVIEWS (2016)
Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B
Hideaki Imamura et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells
Srinivas Mamidi et al.
ONCOIMMUNOLOGY (2015)
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
Ronald P. Taylor et al.
BLOOD (2015)
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
O. Middleton et al.
LEUKEMIA (2015)
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
P. Macor et al.
LEUKEMIA (2015)
A novel method for direct measurement of complement convertases activity in human serum
A. M. Blom et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia
Nisar A. Baig et al.
JOURNAL OF IMMUNOLOGY (2014)
Analyses of CD20 Monoclonal Antibody-Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies
Ronald P. Taylor et al.
MOLECULAR PHARMACOLOGY (2014)
Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome
Marie Frimat et al.
BLOOD (2013)
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
Marcin Okroj et al.
CANCER TREATMENT REVIEWS (2013)
Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
S. Hoerl et al.
LEUKEMIA (2013)
Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement
Marcin Okroj et al.
MEDICAL ONCOLOGY (2013)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies
Aude Servais et al.
KIDNEY INTERNATIONAL (2012)
Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex
Moonhee Lee et al.
NEUROBIOLOGY OF AGING (2012)
Functional Analyses of Complement Convertases Using C3 and C5-Depleted Sera
Marcin Okroj et al.
PLOS ONE (2012)
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
Magdalena Winiarska et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
New drugs for aggressive B-cell and T-cell lymphomas
Niels Murawski et al.
LANCET ONCOLOGY (2010)
Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma Complement/Rituximab Interactions & Clinical Results in Refractory CLL
Abraham Klepfish et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
Dana Gancz et al.
MOLECULAR IMMUNOLOGY (2009)
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
Andy C. Rawstron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer
Marion E. Couch et al.
CLINICAL CANCER RESEARCH (2007)
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome
Elena Goicoechea de Jorge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome
F Vaziri-Sani et al.
KIDNEY INTERNATIONAL (2006)
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia
AD Kennedy et al.
JOURNAL OF IMMUNOLOGY (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Complement determinations in human disease
MM Glovsky et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2004)
A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases
LA Kuttner-Kondo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Share Paper
